Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

844 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.
De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, Janoueix-Lerosey I, Lavarino C, Maris JM, Mora J, Nakagawara A, Oberthuer A, Ohira M, Schleiermacher G, Schramm A, Schulte JH, Wang Q, Westermann F, Speleman F, Vandesompele J. De Preter K, et al. Among authors: vermeulen j. Clin Cancer Res. 2010 Mar 1;16(5):1532-41. doi: 10.1158/1078-0432.CCR-09-2607. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179214 Free article.
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.
Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo S, Scaruffi P, Tonini GP, De Bernardi B, Noguera R, Piqueras M, Cañete A, Castel V, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Michon J, Combaret V, Fischer M, Oberthuer A, Ambros PF, Beiske K, Bénard J, Marques B, Rubie H, Kohler J, Pötschger U, Ladenstein R, Hogarty MD, McGrady P, London WB, Laureys G, Speleman F, Vandesompele J. Vermeulen J, et al. Lancet Oncol. 2009 Jul;10(7):663-71. doi: 10.1016/S1470-2045(09)70154-8. Epub 2009 Jun 8. Lancet Oncol. 2009. PMID: 19515614 Free PMC article.
Predicting outcomes for children with neuroblastoma.
Vermeulen J, De Preter K, Mestdagh P, Laureys G, Speleman F, Vandesompele J. Vermeulen J, et al. Discov Med. 2010 Jul;10(50):29-36. Discov Med. 2010. PMID: 20670596 Free article. Review.
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, De Paepe A, Laureys G, Schulte JH, Schramm A, Van Den Broecke C, Vermeulen J, Van Roy N, Beiske K, Renard M, Noguera R, Delattre O, Janoueix-Lerosey I, Kogner P, Martinsson T, Nakagawara A, Ohira M, Caron H, Eggert A, Cools J, Versteeg R, Speleman F. De Brouwer S, et al. Among authors: vermeulen j. Clin Cancer Res. 2010 Sep 1;16(17):4353-62. doi: 10.1158/1078-0432.CCR-09-2660. Epub 2010 Aug 18. Clin Cancer Res. 2010. PMID: 20719933
miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples.
De Preter K, Mestdagh P, Vermeulen J, Zeka F, Naranjo A, Bray I, Castel V, Chen C, Drozynska E, Eggert A, Hogarty MD, Izycka-Swieszewska E, London WB, Noguera R, Piqueras M, Bryan K, Schowe B, van Sluis P, Molenaar JJ, Schramm A, Schulte JH, Stallings RL, Versteeg R, Laureys G, Van Roy N, Speleman F, Vandesompele J. De Preter K, et al. Among authors: vermeulen j. Clin Cancer Res. 2011 Dec 15;17(24):7684-92. doi: 10.1158/1078-0432.CCR-11-0610. Epub 2011 Oct 26. Clin Cancer Res. 2011. PMID: 22031095 Free PMC article.
MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors.
Mestdagh P, Fredlund E, Pattyn F, Schulte JH, Muth D, Vermeulen J, Kumps C, Schlierf S, De Preter K, Van Roy N, Noguera R, Laureys G, Schramm A, Eggert A, Westermann F, Speleman F, Vandesompele J. Mestdagh P, et al. Among authors: vermeulen j. Oncogene. 2010 Mar 4;29(9):1394-404. doi: 10.1038/onc.2009.429. Epub 2009 Nov 30. Oncogene. 2010. PMID: 19946337
An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours.
Mestdagh P, Fredlund E, Pattyn F, Rihani A, Van Maerken T, Vermeulen J, Kumps C, Menten B, De Preter K, Schramm A, Schulte J, Noguera R, Schleiermacher G, Janoueix-Lerosey I, Laureys G, Powel R, Nittner D, Marine JC, Ringnér M, Speleman F, Vandesompele J. Mestdagh P, et al. Among authors: vermeulen j. Oncogene. 2010 Jun 17;29(24):3583-92. doi: 10.1038/onc.2010.106. Epub 2010 Apr 12. Oncogene. 2010. PMID: 20383195
Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome.
Schramm A, Schowe B, Fielitz K, Heilmann M, Martin M, Marschall T, Köster J, Vandesompele J, Vermeulen J, de Preter K, Koster J, Versteeg R, Noguera R, Speleman F, Rahmann S, Eggert A, Morik K, Schulte JH. Schramm A, et al. Among authors: vermeulen j. Br J Cancer. 2012 Oct 9;107(8):1409-17. doi: 10.1038/bjc.2012.391. Br J Cancer. 2012. PMID: 23047593 Free PMC article.
Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.
Van Maerken T, Speleman F, Vermeulen J, Lambertz I, De Clercq S, De Smet E, Yigit N, Coppens V, Philippé J, De Paepe A, Marine JC, Vandesompele J. Van Maerken T, et al. Among authors: vermeulen j. Cancer Res. 2006 Oct 1;66(19):9646-55. doi: 10.1158/0008-5472.CAN-06-0792. Cancer Res. 2006. PMID: 17018622
ArrayCGH-based classification of neuroblastoma into genomic subgroups.
Michels E, Vandesompele J, De Preter K, Hoebeeck J, Vermeulen J, Schramm A, Molenaar JJ, Menten B, Marques B, Stallings RL, Combaret V, Devalck C, De Paepe A, Versteeg R, Eggert A, Laureys G, Van Roy N, Speleman F. Michels E, et al. Among authors: vermeulen j. Genes Chromosomes Cancer. 2007 Dec;46(12):1098-108. doi: 10.1002/gcc.20496. Genes Chromosomes Cancer. 2007. PMID: 17823929
844 results